Companies with cannabis-based drugs eye IPOs, private funding boost after U.S. reclassification
Companies developing cannabis-based medicines say U.S. moves to loosen restrictions on the drug could unlock private funding and the public markets, providing a lifeline to the struggling cannabis industry.
